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stress-induced lysosomal dysfunction, cell death,





Zinc dyshomeostasis has been recognized as an important mechanism for cell death in acute brain injury. An
increase in the level of free or histochemically reactive zinc in astrocytes and neurons is considered one of the
major causes of death of these cells in ischemia and trauma. Although zinc dyshomeostasis can lead to cell death
via diverse routes, the major pathway appears to involve oxidative stress.
Recently, we found that a rise of zinc in autophagic vacuoles, including autolysosomes, is a prerequisite for lysoso-
mal membrane permeabilization and cell death in cultured brain cells exposed to oxidative stress conditions. The
source of zinc in this process is likely redox-sensitive zinc-binding proteins such as metallothioneins, which release
zinc under oxidative conditions. Of the metallothioneins, metallothionein-3 is especially enriched in the central ner-
vous system, but its physiologic role in this tissue is not well established. Like other metallothioneins, metallothio-
nein-3 may function as metal detoxicant, but is also known to inhibit neurite outgrowth and, sometimes, promote
neuronal death, likely by serving as a source of toxic zinc release. In addition, metallothionein-3 regulates lysosomal
functions. In the absence of metallothionein-3, there are changes in lysosome-associated membrane protein-1 and
-2, and reductions in certain lysosomal enzymes that result in decreased autophagic flux. This may have dual
effects on cell survival. In acute oxidative injury, zinc dyshomeostasis and lysosomal membrane permeabilization
are diminished in metallothionein-3 null cells, resulting in less cell death. But over the longer term, diminished lyso-
somal function may lead to the accumulation of abnormal proteins and cause cytotoxicity.
The roles of zinc and metallothionein-3 in autophagy and/or lysosomal function have just begun to be investi-
gated. In light of evidence that autophagy and lysosomes may play significant roles in the pathogenesis of various
neurological diseases, further insight into the contribution of zinc dynamics and metallothionein-3 function may
help provide ways to effectively regulate these processes in brain cells.
Introduction
Cells have two major protein degradation pathways: the
ubiquitin-proteasome system (UPS), which mainly acts to
clear and recycle short-lived proteins [1], and macroauto-
phagy or autophagy, in which lysosomal degradation is
the final event [2]. This latter pathway degrades waste
proteins and organelles, recycling damaged organelles
and large proteins that cannot be processed via the UPS.
The autophagic pathway usually operates at low levels
under normal conditions, but is rapidly upregulated
under stress conditions, such as starvation, hormonal
imbalances, and oxidative stress [2-4]. Whereas autopha-
gic degradation releases free amino acids and fatty acids
that serve to meet the energy demands of cells in starva-
tion [5], it also removes potentially detrimental abnormal
organelles and misfolded proteins [6].
During the last decade, abnormalities in autophagy
have been suggested to play roles in the pathogenesis of
cancer and neurodegenerative disease, among other dis-
orders [7-15]. For instance, a reduction in autophagy is
observed in various cancer cells [16-18], and internal or
external activators of autophagy, such as Beclin-1
(BECN1), transforming growth factor-b (TGF-b), and
rapamycin, have been shown to effectively reduce tumor
mass in human hepatocellular carcinoma cells and xeno-
grafted breast cancer cell lines [19-21]. There is also
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neurodegenerative conditions, including Alzheimer’sd i s -
ease, Parkinson’s disease, Niemann-Pick type C disease,
and Huntington’s disease [22-26]. Consistent with this,
downregulation of autophagy-activating genes in the
brain results in severe neurodegeneration [23,27,28].
Given the potential clinical importance of autophagy,
there has been rapidly increasing interest in investigating
this process in various disease models.
Recently, we reported that zinc and metallothionein 3
(MT3) have modulatory effects on autophagic vacuole
(AV) formation and lysosomal changes in cultured brain
cells [29-31]. Zinc serves many essential functions in the
body under normal conditions; it is enriched in all cells,
and is absolutely required for cellular development and
survival [32,33]. Accordingly, a severe zinc deficiency
causes developmental anomalies in humans and animals
[34-36]. On the other hand, increased free zinc levels in
a cell can be highly cytotoxic. The toxic role of endo-
genous zinc has been extensively studied, especially in
the context of acute brain injury [37-41], where zinc has
been shown to be capable of causing cell death through
diverse mechanisms. For instance, high levels of intracel-
lular free zinc can activate protein kinase C (PKC), nico-
tinamide adenine dinucleotide phosphate (NADPH)
oxidases [42], p38 mitogen-activated protein kinase
(MAPK) [43-45], poly ADP-ribose polymerase (PARP)
[46,47], p75
NTR-associated death executor (p75
NTR/
NADE), and apoptosis-inducing factor (AIF) [48-50].
Because cells are vulnerable to drastic changes in
intracellular free zinc, they are equipped with a number
of proteins that function to regulate zinc levels. For
instance, zinc transporters (ZnTs) and Zrt- and Irt-like
proteins (ZIPs) function to transfer zinc across mem-
branes [51,52]. In addition, cysteine-rich metallothio-
neins may function as zinc buffers inside cells. Of the
metallothioneins (MTs), MT3 is especially enriched in
the brain [53,54]. Some MT3 zinc-binding sites are
redox modulated, allowing MT3 to accept and release
zinc in response to changes in oxidative status [53-57].
B e c a u s eM T 3c a ni n d u c eo rr e d u c ez i n ct o x i c i t y
depending on context, it may increase or decrease brain
injury, depending on the particular state of MT3. For
example, if apo-forms are predominant, MT3 may
accept zinc, acting as a buffer against rising intracellular
zinc levels. In contrast, if zinc-binding cysteine residues
o fM T 3a r eo x i d i z e d ,M T 3m a yr e l e a s ez i n ca n dc a u s e
more cell death.
However, our recent findings suggest that MT3 may
have more complex effects on cell biology than simply
functioning as a zinc buffer. For instance, astrocytes
from MT3-null mice show altered activity of lyso-
somes–the endpoint in the autophagy pathway [31].
Here, we review the possible roles of zinc and MT3 in
autophagy activation and lysosomal changes under
oxidative stress conditions.
Increases in Zinc under Oxidative Stress Conditions: Role
in Neuronal and Glial Cell Death
The central nervous system contains high levels of zinc,
which is present at about 70-80 ppm in gray matter
[58]. Whereas the majority of brain zinc is tightly bound
to proteins, about 10-20% is localized to certain gluta-
matergic vesicles in a relatively free state (chelatable
zinc) [59-61]. This synaptic zinc may be released upon
neuronal activation, and is involved in signal transmis-
sion/transduction across synapses [35,62-65]. However,
in acute brain injury, the rise of intracellular free zinc
levels contributes to neuronal and astrocytic cell death
[37,66-70]. For example, zinc-induced neurotoxicity is
observed following acute brain injury, such as trauma,
seizures, and ischemia [35,37,38,71-75]. Whereas synap-
tic zinc may trigger toxic cascades in areas such as the
hippocampal CA3 region, where synaptic zinc is espe-
cially enriched in mossy fiber terminals [76,77], intracel-
lular zinc release may play a larger role in most other
brain regions [77-79].
Calcium-overload excitotoxicity is still considered to
be the major mechanism of neuronal death in acute
brain injuries, including focal ischemia [80-82]. How-
ever, calcium excitotoxicity alone may not be a sufficient
to produce infarcts, in which astrocytes and oligoden-
drocytes, which are much less vulnerable to glutamate
[83-85], are also severely damaged. Hence, factors that
contribute to non-neuronal cell death need to be identi-
fied. In our previous study, we found that the infarct
core exhibits markedly increased levels of labile zinc in
all cellular elements [86,87], raising the possibility that
zinc toxicity may contribute to infarct formation. In
fact, oxidative stress, which usually accompanies focal
ischemia, induces increases in labile zinc in astrocytes as
well as neurons [37,88-90].
So, which toxic mechanisms does zinc trigger inside
cells? Studies over the last decade have suggested a
number of different mechanisms that may mediate zinc
neurotoxicity. Activation of PKC, NADPH oxidases,
extracellular signal regulated kinase 1/2 (ERK-1/2), and
PARP by zinc has been shown to cause mainly oxidative
neuronal necrosis [35,42]. In addition, caspase-mediated
apoptosis is induced by the activation of the p75
NTR/
NADE pathway and by AIF released from mitochondria
in zinc-exposed neurons [48-50,91].
Lysosomal Membrane Permeabilization and Zinc
In addition to the above-mentioned mechanisms for
zinc toxicity, we have recently presented evidence that
lysosomal changes may underlie zinc-induced cell death
(Figure 1) [29]. The lysosome is an acidic cytosolic
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glycosidases, phosphatases, proteases, nucleases, pepti-
dases, sulphatases and lipases–that collectively are cap-
able of degrading all cellular components. As such, the
lysosome serves as the main degradative factory in cells,
receiving cargoes from phagosomes, endosomes, and
autophagosomes. Because lysosomal acidic hydrolases
are so potent, their release in combination with cytosolic
acidification can cause cell death through severe break-
down of cellular components as well as activation of cell
death inducers, such as BID. This process is termed
lysosomal membrane permeabilization (LMP) [92].
LMP has been shown to occur in cell death caused by
oxidative stress, calcium overload, p53 activation, and
exposure to lysosomotrophic toxins such as sphingosine
[92,93]. Moreover, several cancer chemotherapeutic
agents have been shown to induce lysosomal changes,
including LMP, in diverse cancer cell types [2]. In the
brain, epileptic injury and ischemic injury may cause
LMP in certain neurons, inducing their death [5,8,29],
and lysosomal enzyme inhibitors may be neuroprotective
against ischemic insults [94-96].
Recently, we presented evidence that LMP is a key
contributor to oxidative and zinc-induced hippocampal
neuronal death [29]. The salient features of this mechan-
ism are as follows: Under normal conditions, free zinc
levels in lysosomes are low. Following exposure to H2O2
or toxic levels of zinc, the level of zinc in lysosomes rises
rapidly and significantly. Next, a substantial fraction of
zinc-laden lysosomes undergo membrane disintegration,
releasing enzymes such as cathepsins. Finally, hippocampal
neuronal death occurs in a zinc- and cathepsin-dependent
manner. These results indicate that zinc-overload in lyso-
somes and lysosomal disruption are key events in oxidative
neuronal death (Figure 1). Interestingly, lysosomes also
accumulate 4-hydroxy-2-nonenal (HNE) adducts in a
zinc-dependent manner, and HNE per se causes LMP,
suggesting that HNE may be one of mediators of lysoso-
mal derangement in oxidative and/or zinc-mediated neu-
ronal death (Figure 1). Further studies will be needed to
Figure 1 Summary diagram depicting zinc and MT3 effects on autophagy and lysosomes. A. Under physiological conditions, normal
signaling involving zinc release from MT3 contributes to the normal progression of autophagy, resulting in the degradation of abnormal protein
aggregates and waste organelles. This pathway may be beneficial for cell survival. B. Under injurious oxidative stress conditions (e.g., H2O2 or
HNE treatment), the events described in (A) are exaggerated. Hence, much more intense zinc release from MT3 is induced, and excess
autophagy is activated. Excess autophagy and excess zinc accumulation in lysosomes ultimately leads to LMP and cell death. C. Downregulation
of MT3 decreases zinc release from MT3, inhibiting lysosomal functions and reducing fusion between autophagosomes and lysosomes, resulting
in a reduced autophagy flux. Under conditions of acute injury, this results in a reduction in both LMP and cell death, but it can be detrimental
to cell survival under conditions of chronic stress by reducing autophagic degradation of abnormal proteins.
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events in zinc toxicity and LMP.
The role of various organelles in cell death has been
extensively studied in recent years. Initially, the focus
was on mitochondria, since this organelle is the main
site of reactive oxygen species (ROS) generation and
because it also contains and/or releases several apopto-
sis-regulating molecules, including B-cell lymphoma 2
(Bcl-2), Bcl-2-associated X protein (Bax), AIF, and cyto-
chrome c [15]. More recently, the endoplasmic reticu-
lum (ER) has received increasing research attention. ER
stress plays an integral role in the unfolded protein-
induced alarm system that activates multiple signaling
pathways, including MAPK, c-Jun N-terminal kinase
(JNK), p38 MAPK, and nuclear factor-B (NF-B) path-
ways [97-101]. Similarly, a recent surge in interest in
autophagy has brought the lysosome to the fore as
another organelle with a major role to play in cell death
mechanisms. In this context, the possibility that cellular
free zinc may function as a link between oxidative stress
and LMP is particularly intriguing.
Then what is the mechanism underlying lysosomal
zinc accumulation? One possible answer is that the
accumulation of zinc in lysosomes may be an exagger-
ated version of a normal physiologic event, involving the
transport of zinc from the cytosol via certain metal
transporters or ionophores. In this case, zinc may serve
as an activator of lysosomal functions. Alternatively,
zinc accumulation may merely be a result of lysosomal
activation, reflecting zinc release from various zinc-bind-
ing proteins inside lysosomes. Although it is unclear
which is the case, the demonstration that the cell-per-
meant zinc chelator TPEN (tetrakis[2-pyridylmethyl]
ethylenediamine) not only blocks the rise in free zinc
levels in lysosomes but also inhibits LMP tends to favor
the former possibility. The precise inter-organelle zinc
dynamics within cells warrant further investigation.
Autophagy and Zinc
The finding that zinc dyshomeostasis is closely con-
nected to lysosomes, the effector organelle for autop-
hagy, prompted us to investigate the possible role of
zinc in the entire autophagic cascade. Autophagy means
“self-eating” in Greek [6,102]. It is evolutionally con-
served in all eukaryotes and serves the essential
self-digestive function of degrading large proteins and
organelles [3,103].
Of the three known types of autophagy–macroauto-
phagy, microautophagy, and chaperone-mediated autop-
hagy [6,104,105]–macroautophagy (or simply autophagy)
is the best characterized. Recent advances in the mole-
cular biology of autophagy have led to the identification
of a number of proteins required for this process,
including the autophagy-related homologs, BECN1 and
ATG5. Microtubule-associated membrane protein-II
(LC3-II), another autophagy-related protein, is inserted
into the outer membrane of autophagosomes and has
been used as a marker for autophagic activation
[106,107]. LC3-II is quite stable and hence easy to
detect. Transfection with GFP- or RFP-LC3 has been
widely used to monitor the autophagic process in living
cells.
Recently, we used this approach in cultured astrocytes,
which are easier to transfect than primary neurons. In
astrocytes, inducers of oxidative stress such as H2O2 or
FeCl2 activate autophagy, as evidenced by increased
LC3-II levels and autophagosome formation (Figure 1).
Interestingly, zinc accumulation occurs in autophago-
somes as it does in lysosomes [30]. Importantly, TPEN
blocks the activation of autophagy by oxidative stress,
suggesting that zinc accumulation has already started at
the level of autophagosomes and plays a role in autop-
hagy progression. It is not yet known whether specific
zinc transporters are responsible for the zinc accumula-
tion. Moreover, it is possible that TPEN effect is not
due to chelation of zinc inside autophagosomes, but
may instead reflect effects on upstream elements in the
signaling cascade, such as inhibition of phosphatidylino-
sitol 3-kinase type III (PI3K type III) activation. In either
case, these data represents the first demonstration that
cellular zinc may play a role in activation of the autop-
hagic process. Whether autophagy thus activated is
functional (i.e., increases autophagic flux) will require
additional study; however, the fact that mutant hunting-
tin protein (mHttp) aggregation is reduced under these
conditions suggests that this may be the case.
One interesting question is whether the role of zinc in
autophagy and LMP is limited to brain cells or is more
generally applicable to other cell types. The fact that
tamoxifen-induced autophagic cell death in MCF-7
breast cancer cells [14] exhibits similar features, such as
zinc accumulation in AVs and LMP [29,30], suggests
that zinc may play a role in autophagy and autophagic
cell death in general. If confirmed, which will require
addition testing in other cell types and diverse models,
modulation of zinc levels may prove to be an effective
therapeutic intervention under conditions in which
abnormalities in autophagy are contributing factors,
such as cancer and neurodegenerative disorders.
MT3: the Source for Zinc in Neurons and Astrocytes
Human genome analyses have revealed that more than a
thousand proteins may contain zinc-binding motifs
[108]. However, most of these proteins bind zinc tightly,
and hence may not normally contribute to fast zinc
dynamics in cells. In contrast, some proteins, such as
MTs, contain zinc-binding sites that are highly sensitive
to redox states [25,109-114]. When cells are exposed to
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rise, apo-forms of MTs (thioneins) may bind more zinc.
Conversely, under conditions in which cells are exposed
to oxidative stress and during signaling events involving
ROS generation, MTs may serve as zinc-donors, raising
free zinc levels (Figure 1) [114]. Consistent with this,
diverse cells exhibit a rise in free zinc levels in response
to stressful extracellular or intracellular stimuli, includ-
ing hormones, cytokines, metals, inflammation, oxidative
agents, and other stresses [115-118]. This increase in
free zinc may stimulate diverse cellular-response signals
[109,110,119,120]
Four isoforms of MT, MT1-4, have been identified in
mammals, all of which have seven metal binding
domains [113,121-124]. MT1 and MT2 are ubiquitously
expressed in all tissues. In contrast, MT3 and MT4 are
expressed mainly (although not exclusively) in the cen-
tral nervous system and squamous epithelia [125-128].
Hence, it is likely that, at least in the brain, MT3 may
serve as a key source for dynamically exchangeable zinc
in cells exposed to various stress stimuli.
MT3 was originally identified as a neuronal growth
inhibitory factor that inhibited outgrowth of rat cortical
neurons in the presence of Alzheimer’sd i s e a s eb r a i n
extracts [57]. This effect is not shared by MT1 or MT2,
and is probably due to the unique presence of a TCPCP
motif within the b-domain of MT3 [117,122,129-131].
The precise mechanism underlying the neurite out-
growth-inhibitory effect of MT3 remains poorly under-
stood, but a number of studies have implicated MT3 in
various neurological conditions. Altered MT3 expression
has been also reported in amyotrophic lateral sclerosis
(ALS) [54], Down syndrome [132], pontosubicular
necrosis [133], Parkinson’s disease, meningitis, and
Creutzfeld-Jakob disease [134].
In addition, MT3 appears to exert both protective and
injury-promoting effects in experimental models of
brain injury. The neuroprotective effects of MT3, which
are presumably due to its metal-chelating and antioxida-
tive effects, are evident in epileptic brain injury [135],
cortical cryolesions [136], a mutant superoxide dismu-
tase 1 (SOD1[G93A]) mouse model of ALS [137], and
peripheral nerve injury [138]. Several researchers have
demonstrated the opposite phenomenon, showing for
example that intracellular zinc released from MT3 may
trigger neuronal death in vivo [77] and in vitro [31],
indicating the injury-promoting effects of MT3 [54,56].
In adult brains, MT3 is predominantly expressed in
neurons, but in developing brains it is also significantly
expressed in astrocytes. We have demonstrated that the
increase in intracellular free zinc induced by oxidative
injury is significantly reduced in cultured MT3-null
astrocytes compared with wild-type cells (Figure 1) [31].
Moreover, cell death is also attenuated in MT3-null
cells. These results provide additional support for the
idea that MT3 is the main source for elevations in toxic
free zinc in acute brain injury. Interestingly, although
astrocytes express substantial amounts of MT1 and
MT2 [120], experiments employing small interfering
RNAs suggest that these MTs do not participate as zinc
donors.
Regulation of Lysosomal Functions by MT3
MT3 may have complex biological functions that extend
well beyond its role as a simple buffer for zinc, as exem-
plified by its initial identification as a neuronal growth
inhibitory factor. Recently, we found that MT3 may reg-
ulate the levels of lysosomal proteins, thus regulating
the function of lysosomes [31]. Specifically, the absence
of MT3 in astrocytes results in changes in the levels of
LMP and altered LMP glycosylation patterns (Figure 1).
Such changes may inhibit docking of upstream vesicles,
such as autophagosomes and endosomes, to lysosomes.
In fact, the levels of autophagic markers such as LC3-II
are markedly increased in astrocytes from MT3-null
mice (Figure 1).
Another interesting change induced by the absence of
MT3 is a reduction in certain hydrolase activities that
implies a decrease in lysosomal protein degradative cap-
ability. The combination of reduced zinc levels and
reduced lysosomal enzyme levels may act to attenuate
LMP and cell death (Figure 1). Moreover, decreased
lysosomal function should lead to diminished autophagic
flux. Consistent with this, we found that cholesterol
metabolism was altered and mHttp aggregates accumu-
lated in the absence of MT3 [31].
How does MT3 regulate lysosomal functions?
Although the available information provides little insight
into this question, one report notes that disruption of
c-Abl, a member of the Abelson family of cytoplasmic
non-receptor tyrosine kinases, has effects on lysosomes
in the A549 alveolar carcinoma cell line that are similar
to those observed in brain cells lacking MT3 [139]. This
suggests that MT3 may be involved in the c-Abl signal-
ing cascade in brain cells. Alternately, adequate free zinc
levels may be required to maintain normal lysosomal
function. Further studies may help determine the
mechanism(s) underlying MT3 effects on lysosomes.
Regardless of the mechanism, because lysosomal func-
tion is linked to autophagy and neurodegenerative disor-
ders, MT3 may prove to be a suitable target for drugs
designed to control lysosomal function. By reducing
toxic zinc accumulation, LMP, and cell death, downre-
gulation of MT3 function may be beneficial in acute
brain injury (Figure 1). Conversely, in neurodegenerative
conditions in which the accumulation of protein aggre-
gates contributes to the pathology, upregulation of
MT3, and the associated enhancement in lysosomal
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(Figure 1).
Conclusions
Recent studies have revealed that free zinc levels change
in various organelles in response to physiologic or
pathological stimuli, and suggest important functional
consequences of these zinc dynamics. One aspect of this
larger picture–the possible roles of free zinc in autopha-
gic and lysosomal functions–has been the focus of this
review. Under oxidative stress conditions, free zinc levels
in the cytosol and lysosomes of cultured neurons and
astrocytes rise, ultimately resulting in LMP and cell
death. While this change may contribute to the cell
death that occurs after acute brain injury, the fact that
free zinc levels rise in AVs (autophagosomes and autoly-
sosomes) following various stimuli is also notable.
Because reducing the levels of free zinc with TPEN
b l o c k sa l lt h e s ec h a n g e s ,t h er i s eo ff r e ez i n ci nA V s
may play a role in the progression of the autophagic
cascade. In brain cells, the source of free zinc may be
MT3. In support of a role for MT3 in lysosomal func-
tion, the absence of MT3 results in drastic changes in
the levels of lysosomal proteins and results in reduced
lysosomal degradative capacity. Further studies will be
needed to elucidate the mechanism by which MT3 regu-
lates lysosomal functions.
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